This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. 6105 or Piper Sandler & Co., 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, Attention: Prospectus Department, by email at or by telephone at (800) 747-3924. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by email at or by telephone at (866) 803-9204 SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by email at or by telephone at (800) 808-7525, ext. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website located at When available, electronic copies of the preliminary prospectus supplement and the accompanying prospectus may also be obtained from: J.P. The offering may be made only by means of a prospectus supplement and accompanying prospectus. The offering is being made pursuant to a shelf registration statement, including a base prospectus, filed by RAPT with the Securities and Exchange Commission (SEC), which was declared effective by the SEC on November 16, 2020. Cantor is acting as book-running manager for the proposed offering. Morgan, SVB Leerink and Piper Sandler are acting as joint lead book-running managers for the proposed offering.
The proposed offering is subject to market conditions, and there can be no assurance as to whether or when the proposed offering may be completed or as to the actual size or terms of the proposed offering. All of the shares of common stock are being offered by RAPT. In addition, RAPT expects the underwriters to be granted a 30-day option to purchase up to an additional $18.75 million of its common stock on the same terms and conditions. The story looked even better with patients experiencing a 50% improvement in EASI score - 42.9% of patients treated with RPT193 achieved this marked improvement compared to only 10% of patients in the placebo group.SOUTH SAN FRANCISCO, Calif., J(GLOBE NEWSWIRE) - RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced that it has commenced an underwritten public offering of $125 million of its common stock. That was more than twice the 17% improvement seen in patients on a placebo.
Patients treated with the company's experimental drug achieved a 36.3% improvement in the Eczema Area and Severity Index (EASI) score from baseline. You'd expect that RAPT's results from the early-stage study of RPT193 had to be fantastic for the biotech stock to more than double. The huge gain came after the company announced positive top-line results from a phase 1b clinical study evaluating RPT193 in treating moderate-to-severe atopic dermatitis. RAPT Therapeutics ( NASDAQ:RAPT) stock was crushing it on Monday, with shares skyrocketing 110.4% as of 11:59 a.m. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics.
0 kommentar(er)
